IFM Therapeutics is focused on developing innovative therapies that target the innate immune system to address inflammation-driven diseases and cancer. Their approach involves creating first-in-class small molecules that can precisely modulate immune responses, thereby enhancing or controlling the innate immune system's activity. The company has identified key targets, such as the NLRP3 and cGAS/STING pathways, which play significant roles in various inflammatory and autoimmune conditions. By blocking or activating these pathways, IFM aims to develop treatments for a range of diseases, including systemic lupus erythematosus, inflammatory bowel disease, and various cancers, while also exploring the potential for synergy with existing therapies like checkpoint inhibitors.

The technologies employed by IFM Therapeutics leverage advancements in understanding innate immune biology, which has revealed that many diseases are driven by inappropriate activation of the innate immune system. Their drug candidates are designed to selectively modulate this system, addressing the underlying drivers of disease rather than just the symptoms. This precision medicine approach is supported by human genetic evidence that links specific innate immune sensors to both rare and common diseases. By focusing on the innate immune system, IFM Therapeutics aims to provide more effective and safer therapeutic options for patients suffering from chronic inflammatory conditions and cancer.

United States

At IFM Therapeutics, we work to improve the lives of patients with inflammatory disorders and cancer by developing transformative medicines that precisely target the innate immune system, the body’s first line of immunological response and an essential component of immune function.

IFM Therapeutics

Company Details